Drive Times to Opioid Treatment Programs in Urban and Rural Counties in 5 US States

Methadone for opioid use disorder can be dispensed only from US Substance Abuse and Mental Health Services Administration (SAMHSA)-certified opioid treatment programs (OTPs), creating access barriers in rural counties with a shortage of facilities. Canada and Australia allow primary care prescribing and pharmacy dispensing of methadone to expand access. Therefore, we examined drive times to the nearest OTP in urban and rural counties in 5 US states with the highest county rates of opioid-related overdose mortality. In addition, we compared drive times to federally qualified health centers (FQHCs) as potential primary care methadone-prescribing locations and to dialysis centers as treatment locations for a different chronic disease requiring frequent engagement.

Methods | The outcome was the minimum drive time in minutes from the county mean center of population to the nearest OTP, FQHC, and dialysis center using the Esri ArcGIS rural drive-time tool (September 2017 version), which simulates automobile movement between 2 points along a national street network based on historical average speeds. From the 2010 US Census, we obtained the coordinates of the county mean center of population for all counties in Indiana, Kentucky, Ohio, Virginia, and West Virginia, excluding counties with geographic changes after the census. We geocoded 2017 OTP, FQHC, and dialysis center street addresses from the SAMHSA OTP Directory and the Health Resources and Services Administration data warehouse. Addresses not matched during batch geocoding were hand reviewed. We excluded school-based FQHCs and facilities remaining unmatched after hand review.

We stratified counties by the 2013 National Center for Health Statistics urban-rural county classification scheme, dividing counties into urban (large central metros, large fringe metros, medium metros, and small metros) and rural (micropolitan and noncore) levels (Table). We assessed the association across urban-rural classification using Welch analysis of variance. We used a paired t test to compare drive times to the nearest OTP with drive times to the nearest FQHC or dialysis center, using a Bonferroni correction for multiple comparisons. Hypothesis tests were 2-sided with α=.05. We completed our analyses in Stata 15 (StatCorp).

Results | Of the 487 of 489 counties included, 270 (55.3%) were rural. Within the 5 states, 109 OTPs, 952 FQHCs, and 837 dialysis centers were included. Among all counties, the mean drive time to the nearest OTP was 37.3 (95% CI, 35.5-39.1) minutes and the mean drive time to the nearest OTP increased from 7.8 (95% CI, 5.7-9.9) minutes in the urban classification to 49.1 (95% CI, 46.3-51.8) minutes in the noncore rural classification (P < .001; Table). The mean drive time to the nearest FQHC was 15.8 (95% CI, 14.8-16.9) minutes (difference with OTP, 21.5 [95% CI, 19.5-23.4] minutes) and to the nearest dialysis center was 15.1 (95% CI, 14.1-16.2) minutes (difference with OTP, 22.1 [95% CI, 20.5-23.8] minutes). Longer drive times for OTPs vs FQHCs and dialysis centers were found for all urban-rural classifications (Figure) except large central metros, with the greatest difference in rural counties.

<table>
<thead>
<tr>
<th>Classification</th>
<th>Drive Time, Mean (95% CI), min</th>
<th>Difference in Drive Time, Mean (95% CI), min</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>To OTP</td>
<td>To OTP vs FQHC</td>
</tr>
<tr>
<td>All counties</td>
<td>37.3 (35.5 to 39.1)</td>
<td>15.8 (14.8 to 16.9)</td>
</tr>
<tr>
<td></td>
<td>&lt;.001</td>
<td>21.5 (19.5 to 23.4)</td>
</tr>
<tr>
<td>Noncore</td>
<td>49.1 (46.3 to 51.8)</td>
<td>17.3 (15.4 to 19.2)</td>
</tr>
<tr>
<td></td>
<td>&lt;.001</td>
<td>31.7 (28.3 to 35.2)</td>
</tr>
<tr>
<td>Micropolitan</td>
<td>41.1 (37.7 to 44.6)</td>
<td>15.7 (13.2 to 18.2)</td>
</tr>
<tr>
<td></td>
<td>&lt;.001</td>
<td>25.4 (21.6 to 29.2)</td>
</tr>
<tr>
<td>Small metro</td>
<td>35.0 (29.4 to 40.6)</td>
<td>14.7 (11.8 to 17.6)</td>
</tr>
<tr>
<td></td>
<td>&lt;.001</td>
<td>20.3 (14.3 to 26.3)</td>
</tr>
<tr>
<td>Medium metro</td>
<td>21.1 (17.7 to 24.5)</td>
<td>13.4 (11.0 to 15.7)</td>
</tr>
<tr>
<td></td>
<td>&lt;.001</td>
<td>7.8 (4.8 to 10.7)</td>
</tr>
<tr>
<td>Large fringe metro</td>
<td>25.2 (22.5 to 27.9)</td>
<td>16.2 (13.8 to 18.6)</td>
</tr>
<tr>
<td></td>
<td>&lt;.001</td>
<td>9.0 (6.1 to 12.0)</td>
</tr>
<tr>
<td>Large central metro</td>
<td>7.8 (5.7 to 9.9)</td>
<td>6.3 (3.4 to 9.2)</td>
</tr>
<tr>
<td></td>
<td>.06</td>
<td>1.4 (~1.7 to 4.5)</td>
</tr>
</tbody>
</table>

Abbreviations: FQHC, Federally Qualified Health Center; OTP, opioid treatment program.

© 2019 American Medical Association. All rights reserved.
Discussion | Rural county classification was associated with longer drive times to the nearest OTP compared with urban counties. Drive times to OTPs were longer than to FQHCs or dialysis centers. The greater geographic availability of hemodialysis, which requires engagement 3 times a week, contrasts with methadone treatment availability, for which federal law requires engagement 6 times a week for medication dispensing. Enabling FQHC methadone provision in the United States, mirroring practices in Canada and Australia, would expand geographic access without construction of additional facilities and may further integrate opioid use disorder treatment into primary care. An alternative path to improving access would be constructing new OTPs, as was done previously with dialysis centers whose access was expanded by the 1972 extension of Medicare disability coverage,4 although this would require significantly more investment in rural health care infrastructure. Limitations include that drive times were county-level population estimates, individual drive times within counties vary, and smaller geographic units would improve drive time estimation. County estimates are presented given the importance of local government approval of OTPs. The urban geographic availability of methadone was likely overestimated because of public transportation.

Paul J. Joudrey, MD, MPH
E. Jennifer Edelman, MD, MHS
Emily A. Wang, MD, MAS

Accepted for Publication: August 1, 2019.

Corresponding Author: Paul J. Joudrey, MD, MPH, National Clinician Scholars Program, Yale School of Medicine, 333 Cedar St, Sterling Hall of Medicine IE-68, PO Box 208088, New Haven, CT 06520 (paul.joudrey@yale.edu).

Author Contributions: Dr Joudrey had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Joudrey, Wang. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: Joudrey. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Joudrey. Supervision: Wang.

Conflict of Interest Disclosures: None reported.

Funding/Support: Funding for this publication was provided by the Department of Veterans Affairs Office of Academic Affiliations through the National Clinician Scholars Program and by Clinical and Translational Science Award grant number TL1 TR001864 from the National Center for Advancing Translational Science and grant number SK12DA033312 from the National Institute on Drug Abuse, both components of the National Institutes of Health (NIH).

Role of the Funder/Sponsor: The funders played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication.

Disclaimer: The contents are solely the responsibility of the authors and do not necessarily represent the official view of the NIH or the Department of Veterans Affairs.

Additional Contributions: We thank Miriam Olivares, MS, of Yale University for providing technical assistance with ArcGIS online. No compensation was provided for her contribution.


Metformin for Type 2 Diabetes

To the Editor Drs Flory and Lipska1 reviewed the literature on metformin, analyzing several aspects such as its mechanism of action, clinical use, and safety.

The efficacy of metformin has also been investigated in other studies, comparing it with other drugs already in use. In the short and medium term, metformin has shown an efficacy comparable with sulfonylureas, without exposing the patient to hypoglycemic risk, and to acarbose and pioglitazone, and with efficacy higher than dipeptidyl peptidase 4 (DPP-4) inhibitors but lower than glucagon-like peptide 1 (GLP-1) receptor agonists. In long-term monotherapy, metformin shows an increased efficacy compared with sulfonylureas.2

In addition, in patients with type 2 diabetes aged 10 to 16 years, several randomized studies have shown an efficacy and tolerability of metformin similar to that in adults.3 In elderly individuals, because of renal function impairment, patients may become ineligible for metformin.4 In these patients, the risk of developing metformin-induced lactic acidosis increases. However, the incidence of this adverse event has decreased over time, thanks to an education campaign by specialists on the proper use of metformin in patients at risk, with a decrease in incidence from 76.8 cases per 100 000 in 2010 to 32.9 cases per 100 000 in 2014.4 The use of metformin in elderly men with type 2 diabetes showed a reduced risk of all-cause mortality and age-related comorbidities such as cardiovascular diseases, neoplasms, dementia, depression, and frailty.5

In patients who do not tolerate metformin, sulfonylureas represent a good option; however, insufficient data are available to assess differences in outcomes (hospitalization, complications, all-cause death) or cost-effectiveness, or compared with long-term use of new brand-name drugs.

Alfredo Caturano, MD
Raffaele Galiero, MD
Pia Clara Pafundi, PhD

Author Affiliations: Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy.

Corresponding Author: Alfredo Caturano, MD, Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Piazza Luigi Miraglia 2, Naples 80138, Italy (alfredo.caturano@virgilio.it).

Conflict of Interest Disclosures: None reported.

References


To the Editor In their Clinical Update on metformin, Drs Flory and Lipska succinctly highlighted metformin’s robust safety data and low cost, rendering it a good first-line pharmacologic treatment for type 2 diabetes in most patients. We agree with their conclusion but wish to mention metformin-induced vitamin B12 deficiency, an elusive yet common and potentially reversible adverse effect of long-term metformin use that may have implications for patients’ quality of life.

Symmetrical polyneuropathy is the most common form of neuropathy associated with diabetes and vitamin B12 deficiency. A symmetrical lower extremity sensorimotor polyneuropathy in patients with diabetes on metformin may masquerade as diabetic neuropathy, prompting clinicians to add superfluous pharmacologic therapies such as gabapentin or pregabalin.

Instead, many cases of diabetic neuropathy may represent vitamin B12 deficiency. Observational studies suggest that as much as 30% of patients with diabetes taking metformin develop clinically significant vitamin B12 deficiency.2 Vitamin B12 deficiency has been associated with larger doses and long-term use (>6 months) of metformin. In a recent meta-analysis of 31 studies, patients with diabetes taking metformin had a significantly higher risk of developing vitamin B12 deficiency compared with patients not taking metformin (relative risk, 2.09 [95% CI, 1.49-2.93]; P = .0001).3 Metformin alters ileal enterocyte calcium-dependent membranes, which impair vitamin B12-intrinsic factor absorption and can be partially reversed by calcium intake.4

Treating vitamin B12 deficiency is straightforward and risk free and may have profound implications for a patient’s quality of life, with symptoms related to peripheral neuropathy improving in as little as 3 months.5 Hence, we suggest that patients with diabetes taking long-term metformin therapy undergo annual screening for vitamin B12 deficiency using a serum vitamin B12 measurement. In patients with a normal-range serum vitamin B12 level who have an unexplained macrocytosis, peripheral neuropathy despite glycemic control, or other risk factors for vitamin B12 deficiency (eg, concomitant proton pump inhibitor use, vegan diet), we recommend obtaining a serum methylmalonic acid measurement.

Jayshil J. Patel, MD
Manpreet S. Mundi, MD